[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334257-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334257-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","changes-in-essential-cancer-medicines-and-association-with-cancer-outcomes-an-observational-study-of-158-countries","Changes in essential cancer medicines and association with cancer outcomes - an observational study of 158 countries","","Cancer is a major cause of mortality worldwide, and cross-country differences in cancer outcomes partly reflect unequal access to cancer care, including medicines. National essential medicines lists (NEMLs) can shape healthcare spending prioritization and medicine availability. This study evaluates how amenable cancer mortality relates to medicines included in NEMLs for eight cancers and summarizes changes in cancer treatment listings across 158 countries using cross-sectional analyses of NEMLs obtained in May 2023.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/changes-in-essential-cancer-medicines-and-association-with-cancer-outcomes-an-observational-study-of-158-countries/334257/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/changes-in-essential-cancer-medicines-and-association-with-cancer-outcomes-an-observational-study-of-158-countries/334257.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study examine?","Question",{"text":63,"@type":64},"The study examines the association between amenable cancer mortality and the medicines included in national essential medicines lists for eight cancers, and it summarizes changes in cancer treatment inclusion across 158 countries.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the national essential medicines lists (NEMLs) and cancer medicines handled in the analysis?",{"text":68,"@type":64},"NEMLs for 158 countries were obtained in May 2023, cancer medicines used to manage each of the eight cancers were identified, and the number of listed medicines per cancer was determined for each country.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings and which cancers showed associations?",{"text":72,"@type":64},"Associations were found for six of eight cancers—non-melanoma skin, uterine, breast, Hodgkin lymphoma, colon, and leukemia—after adjusting for healthcare expenditure and population size.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334257,1791102596,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Ul Haq et al. BMC Cancer (2024) 24:1526 [https://doi.org/10.1186/s12885-024-13247-w](https://doi.org/10.1186/s12885-024-13247-w)  \nBMC Cancer  \n RESEARCH Open Access  \nChanges in essential cancer medicinesand association with cancer outcomes: an observational study of 158 countries  \nMoizza Zia Ul Haq1, Camila Heredia 1, Adelaide Buadu 1, Amal Rizvi 1, Aine Workentin1 and Nav Persaud1,2*  \nAbstract  \nBackground Cancer is a major cause of mortality worldwide, and differences in cancer mortality rates  \nbetween countries are, in part, due to differences in access to cancer care, including medicines. National essential medicines lists (NEMLs) play a role in prioritization of healthcare expenditure and access to medicines. We examined the association between amenable cancer mortality and listing medicines used in the management of eight cancers (non-melanoma skin, uterine, breast, Hodgkin lymphoma, colon, leukemia, cervical, and testicular) in national essential medicines lists of 158 countries and summarized changes to the inclusion of cancer treatments in NEMLs. Methods We conducted a cross-sectional examination of NEMLs for 158 countries, which were obtained in May 2023. We identified medicines used to treat each of the eight cancers and determined the number of medicines listed by NEMLs for each cancer. We conducted multiple linear regressions to examine the association between the number of medicines listed on the NEMLs and cancer mortality.  \nResults We found associations between cancer medicine listing and outcomes for six of the eight examined cancers (non-melanoma skin cancer (p = 0 . 001), uterine cancer (p = 0 . 006), breast cancer (p = 0 . 001), Hodgkin lymphoma (p = 0 . 021), colon cancer (p = 0 . 006), and leukemia (p = 0 . 002)), when adjusting for healthcare expenditure and population size.  \nConclusion There was an association between listing cancer medicines on NEMLs and cancer mortality. Further research is required to explore how cancer mortality may be impacted by other cancer interventions, as well as policies to improve equitable access to cancer care.  \nKeywords Essential medicines, Cancer medicines, Access to medicines  \n*Correspondence: Nav Persaud [nav.persaud@utoronto.ca](nav.persaud@utoronto.ca)  \n1 MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON M5B 1T8, Canada  \n2 Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada  \nBackground  \nCancer is a major cause of mortality globally – in 2020 alone, there were an estimated 19.3 million new cases of cancer and almost 10 million cancer deaths, and cancer incidence and mortality is rapidly increasing [1]. Differences in mortality rates between countries rates are due to differences in risk factors and access to cancer care, including medicines [1].  \nThe World Health Organization (WHO) has developed and updated Model Lists of Essential medicines, consisting of medicines “intended to be available in functioning  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://crea","cbCaimit5M8ubtxL","https://ap.wps.com/l/cbCaimit5M8ubtxL","pdf",1089746,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What question does the study examine?\",\"answer\":\"The study examines the association between amenable cancer mortality and the medicines included in national essential medicines lists for eight cancers, and it summarizes changes in cancer treatment inclusion across 158 countries.\"},{\"question\":\"How were the national essential medicines lists (NEMLs) and cancer medicines handled in the analysis?\",\"answer\":\"NEMLs for 158 countries were obtained in May 2023, cancer medicines used to manage each of the eight cancers were identified, and the number of listed medicines per cancer was determined for each country.\"},{\"question\":\"What were the main findings and which cancers showed associations?\",\"answer\":\"Associations were found for six of eight cancers—non-melanoma skin, uterine, breast, Hodgkin lymphoma, colon, and leukemia—after adjusting for healthcare expenditure and population size.\"}]","Changes in essential cancer medicines and association with cancer outcomes - an observational study of 158 countries | PDF",1790006007]